ConductScience.org, home

Paper9683207

Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study.

Reijers MH and 12 others. Lancet, 1998. Cited by 138 papers, by iCite.

Cite this record

ConductScience Library. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Papers, record 9683207. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9683207

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study.
PubMed
Journal
Lancet
PubMed
Year
1998
PubMed
Publication types
Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
138
iCite
Relative citation ratio, by iCite
3.36
iCite
Revised in PubMed
2019-06-11
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Reijers MHM H
2Weverling GJG J
3Jurriaans SS
4Wit FWF W
5Weigel HMH M
6Ten Kate RWR W
7Mulder JWJ W
8Frissen PHP H
9van Leeuwen RR
10Reiss PP
11Schuitemaker HH
12de Wolf FF
13Lange JMJ M

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-HIV AgentsMajor topic
HIV InfectionsMajor topic
HIV-1Major topic
Adult
CD4 Lymphocyte Count
CD8-Positive T-Lymphocytes
Drug Therapy, Combination
Feasibility Studies
Female
Follow-Up Studies
Humans
Lymphocyte Count
Male
RNA, Viral
Time Factors
Virus Replication

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00084019Atazanavir/Ritonavir Maintenance TherapyBackground

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in9798619Amsterdam Duration of Antiretroviral Medication (ADAM) study.https://conductscience.org/library/papers/9798619

Source PubMed

Download CSV of comments and corrections

Cited by23

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 138 citations.

PMIDTitleJournalYearIn PapersSource
39556960Risk of viral failure after simplification therapy without using integrase inhibitors compared with maintenance of triple antiretroviral therapy: A systematic review and meta-analysis.Braz J Infect Dis2024https://conductscience.org/library/papers/39556960PubMed
26872331Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens.PLoS One2016https://conductscience.org/library/papers/26872331PubMed
26849060Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients.PLoS One2016https://conductscience.org/library/papers/26849060PubMed
26677129Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.Drugs2016https://conductscience.org/library/papers/26677129PubMed
24802242Baseline natural killer and T cell populations correlation with virologic outcome after regimen simplification to atazanavir/ritonavir alone (ACTG 5201).PLoS One2014https://conductscience.org/library/papers/24802242PubMed
21034506Predictors of adherence to antiretroviral therapy among people living with HIV/AIDS in resource-limited setting of southwest ethiopia.AIDS Res Ther2010https://conductscience.org/library/papers/21034506PubMed
20064271Modelling imperfect adherence to HIV induction therapy.BMC Infect Dis2010https://conductscience.org/library/papers/20064271PubMed
19787058The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy.PLoS One2009https://conductscience.org/library/papers/19787058PubMed
19320232Simplification strategies to reduce antiretroviral drug exposure: progress and prospects.Antivir Ther2009https://conductscience.org/library/papers/19320232PubMed
17630827Optimal timing and duration of induction therapy for HIV-1 infection.PLoS Comput Biol2007https://conductscience.org/library/papers/17630827PubMed
16920824Possible therapeutic vaccine strategy against human immunodeficiency virus escape from reverse transcriptase inhibitors studied in HLA-A2 transgenic mice.J Virol2006https://conductscience.org/library/papers/16920824PubMed
14766874Different viral rebound following discontinuation of antiretroviral therapy in cases of infection with viruses carrying L74V or thymidine-associated mutations.J Clin Microbiol2004https://conductscience.org/library/papers/14766874PubMed
14583945Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection.Cochrane Database Syst Rev2003https://conductscience.org/library/papers/14583945PubMed
12866987When to Start Antiretroviral Therapy and What to Start With-- A European Perspective.Curr Infect Dis Rep2003https://conductscience.org/library/papers/12866987PubMed
12204968Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients.Clin Diagn Lab Immunol2002https://conductscience.org/library/papers/12204968PubMed
12000245Accelerated publication versus usual publication in 2 leading medical journals.CMAJ2002https://conductscience.org/library/papers/12000245PubMed
11782542Structured intermittent treatment for HIV disease: Necessary concession or premature compromise?Proc Natl Acad Sci U S A2002https://conductscience.org/library/papers/11782542PubMed
11095802Reservoirs for HIV-1.Curr Infect Dis Rep1999https://conductscience.org/library/papers/11095802PubMed
10727446Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.J Clin Invest2000https://conductscience.org/library/papers/10727446PubMed
10721504Design of dimerization inhibitors of HIV-1 aspartic proteinase: a computer-based combinatorial approach.J Comput Aided Mol Des2000https://conductscience.org/library/papers/10721504PubMed

See all 23 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/9683207

GET https://conductscience.org/api/papers/v1/9683207/cited_by?page=2